Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate cancer (mCRPC). In the non-randomised, multicohort, global p...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2022-01, Vol.160, p.61-71 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 71 |
|---|---|
| container_issue | |
| container_start_page | 61 |
| container_title | European journal of cancer (1990) |
| container_volume | 160 |
| creator | Fizazi, Karim González Mella, Pablo Castellano, Daniel Minatta, Jose N. Rezazadeh Kalebasty, Arash Shaffer, David Vázquez Limón, Juan C. Sánchez López, Héctor M. Armstrong, Andrew J. Horvath, Lisa Bastos, Diogo A. Amin, Neha P. Li, Jia Unsal-Kacmaz, Keziban Retz, Margitta Saad, Fred Petrylak, Daniel P. Pachynski, Russell K. |
| description | Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate cancer (mCRPC).
In the non-randomised, multicohort, global phase II CheckMate 9KD trial, 84 patients with chemotherapy-naive mCRPC, ongoing androgen deprivation therapy and ≤2 prior novel hormonal therapies (NHTs) received nivolumab 360 mg and docetaxel 75 mg/m2 every 3 weeks with prednisone 5 mg twice daily (≤10 cycles) and then nivolumab 480 mg every 4 weeks (≤2 years). The co-primary end-points were objective response rate (ORR) and prostate-specific antigen response rate (PSA50-RR; ≥50% decrease from baseline).
The confirmed ORR (95% confidence interval [CI]) was 40.0% (25.7–55.7), and the confirmed PSA50-RR (95% CI) was 46.9% (35.7–58.3). The median (95% CI) radiographic progression-free survival (rPFS) and overall survival (OS) were 9.0 (8.0–11.6) and 18.2 (14.6–20.7) months, respectively. In subpopulations with versus without prior NHT, the ORR was 38.7% versus 42.9%, the PSA50-RR was 39.6% versus 60.7%, the median rPFS was 8.5 versus 12.0 months and the median OS was 16.2 months versus not reached. Homologous recombination deficiency status or tumour mutational burden did not appear to impact efficacy. The most common any-grade and grade 3–4 treatment-related adverse events were fatigue (39.3%) and neutropenia (16.7%), respectively. Three treatment-related deaths occurred (1 pneumonitis related to nivolumab; 2 pneumonias related to docetaxel).
Nivolumab plus docetaxel has clinical activity in patients with chemotherapy-naïve mCRPC. Safety was consistent with the individual components. These results support further investigation in the ongoing phase III CheckMate 7DX trial.
NCT03338790.
•Nivolumab plus docetaxel has clinical activity in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.•Safety of the combination is consistent with that of the individual components.•These data support further investigation in the ongoing phase III CheckMate 7DX trial. |
| doi_str_mv | 10.1016/j.ejca.2021.09.043 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2600823503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0959804921011448</els_id><sourcerecordid>2625331469</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3433-f73e21cb65c5716d6c5791ed57b6ad7643308fbc3b051e98dab7f86844ebdb353</originalsourceid><addsrcrecordid>eNp9kU2O1DAQhS0EYpqBC7BAltiwSbDjxLERG9T8tRhgA2vLcSqKm_xhOw1zF-7AIbgYFfXAggWrKvl99VTlR8hDznLOuHx6zOHobF6wgudM56wUt8iOq1pnTFXFbbJjutKZYqW-IPdiPDLGalWyu-RClIoVSpY78uODP83DOtqGLsMaaTs7SPY7DNRPdLHJw5Qi_eZTT10P45x6CHa5zib76-cJ6IhwTIg56rAJ2M1TFiB6fJ0SXcK8yYDq5CA8oyitAzp2YR4pmtGltxHo4UD3Pbgv7zdWv3tJU_B2uE_udHaI8OCmXpLPr1992r_Nrj6-OexfXGVOlEJkXS2g4K6RlatqLluJRXNoq7qRtq0lMkx1jRMNqzho1dqm7pRUZQlN24hKXJInZ19c9-sKMZnRRwfDYCeY12gKyZgqRMUEoo__QY_zGibcDqmiEoKXUiNVnCmH98cAnVmCH224NpyZLTtzNFt2ZsvOMG0wOxx6dGO9NiO0f0f-hIXA8zMA-BcnD8FEh_k4aH0Al0w7-__5_wbMV62p</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2625331469</pqid></control><display><type>article</type><title>Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Fizazi, Karim ; González Mella, Pablo ; Castellano, Daniel ; Minatta, Jose N. ; Rezazadeh Kalebasty, Arash ; Shaffer, David ; Vázquez Limón, Juan C. ; Sánchez López, Héctor M. ; Armstrong, Andrew J. ; Horvath, Lisa ; Bastos, Diogo A. ; Amin, Neha P. ; Li, Jia ; Unsal-Kacmaz, Keziban ; Retz, Margitta ; Saad, Fred ; Petrylak, Daniel P. ; Pachynski, Russell K.</creator><creatorcontrib>Fizazi, Karim ; González Mella, Pablo ; Castellano, Daniel ; Minatta, Jose N. ; Rezazadeh Kalebasty, Arash ; Shaffer, David ; Vázquez Limón, Juan C. ; Sánchez López, Héctor M. ; Armstrong, Andrew J. ; Horvath, Lisa ; Bastos, Diogo A. ; Amin, Neha P. ; Li, Jia ; Unsal-Kacmaz, Keziban ; Retz, Margitta ; Saad, Fred ; Petrylak, Daniel P. ; Pachynski, Russell K.</creatorcontrib><description>Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate cancer (mCRPC).
In the non-randomised, multicohort, global phase II CheckMate 9KD trial, 84 patients with chemotherapy-naive mCRPC, ongoing androgen deprivation therapy and ≤2 prior novel hormonal therapies (NHTs) received nivolumab 360 mg and docetaxel 75 mg/m2 every 3 weeks with prednisone 5 mg twice daily (≤10 cycles) and then nivolumab 480 mg every 4 weeks (≤2 years). The co-primary end-points were objective response rate (ORR) and prostate-specific antigen response rate (PSA50-RR; ≥50% decrease from baseline).
The confirmed ORR (95% confidence interval [CI]) was 40.0% (25.7–55.7), and the confirmed PSA50-RR (95% CI) was 46.9% (35.7–58.3). The median (95% CI) radiographic progression-free survival (rPFS) and overall survival (OS) were 9.0 (8.0–11.6) and 18.2 (14.6–20.7) months, respectively. In subpopulations with versus without prior NHT, the ORR was 38.7% versus 42.9%, the PSA50-RR was 39.6% versus 60.7%, the median rPFS was 8.5 versus 12.0 months and the median OS was 16.2 months versus not reached. Homologous recombination deficiency status or tumour mutational burden did not appear to impact efficacy. The most common any-grade and grade 3–4 treatment-related adverse events were fatigue (39.3%) and neutropenia (16.7%), respectively. Three treatment-related deaths occurred (1 pneumonitis related to nivolumab; 2 pneumonias related to docetaxel).
Nivolumab plus docetaxel has clinical activity in patients with chemotherapy-naïve mCRPC. Safety was consistent with the individual components. These results support further investigation in the ongoing phase III CheckMate 7DX trial.
NCT03338790.
•Nivolumab plus docetaxel has clinical activity in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.•Safety of the combination is consistent with that of the individual components.•These data support further investigation in the ongoing phase III CheckMate 7DX trial.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/j.ejca.2021.09.043</identifier><identifier>PMID: 34802864</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Aged, 80 and over ; Antigens ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Castration ; Chemotherapy ; Clinical trial ; Cohort Studies ; Confidence intervals ; Deprivation ; Docetaxel ; Docetaxel - pharmacology ; Docetaxel - therapeutic use ; Homologous recombination ; Homology ; Humans ; Immunostimulation ; Immunotherapy ; Male ; Metastases ; Metastasis ; Metastatic castration-resistant prostate cancer ; Microenvironments ; Middle Aged ; Monoclonal antibodies ; Neutropenia ; Nivolumab ; Nivolumab - pharmacology ; Nivolumab - therapeutic use ; Patients ; Pneumonitis ; Prednisone ; Prostate cancer ; Prostate-specific antigen ; Prostatic Neoplasms, Castration-Resistant - drug therapy ; Response rates ; Subpopulations ; Survival ; Targeted cancer therapy ; Tumor microenvironment ; Tumors</subject><ispartof>European journal of cancer (1990), 2022-01, Vol.160, p.61-71</ispartof><rights>2021 The Authors</rights><rights>Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Science Ltd. Jan 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3433-f73e21cb65c5716d6c5791ed57b6ad7643308fbc3b051e98dab7f86844ebdb353</citedby><cites>FETCH-LOGICAL-c3433-f73e21cb65c5716d6c5791ed57b6ad7643308fbc3b051e98dab7f86844ebdb353</cites><orcidid>0000-0002-3531-1920 ; 0000-0001-7012-1754 ; 0000-0002-3701-5084 ; 0000-0002-8966-7631</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejca.2021.09.043$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34802864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>González Mella, Pablo</creatorcontrib><creatorcontrib>Castellano, Daniel</creatorcontrib><creatorcontrib>Minatta, Jose N.</creatorcontrib><creatorcontrib>Rezazadeh Kalebasty, Arash</creatorcontrib><creatorcontrib>Shaffer, David</creatorcontrib><creatorcontrib>Vázquez Limón, Juan C.</creatorcontrib><creatorcontrib>Sánchez López, Héctor M.</creatorcontrib><creatorcontrib>Armstrong, Andrew J.</creatorcontrib><creatorcontrib>Horvath, Lisa</creatorcontrib><creatorcontrib>Bastos, Diogo A.</creatorcontrib><creatorcontrib>Amin, Neha P.</creatorcontrib><creatorcontrib>Li, Jia</creatorcontrib><creatorcontrib>Unsal-Kacmaz, Keziban</creatorcontrib><creatorcontrib>Retz, Margitta</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Petrylak, Daniel P.</creatorcontrib><creatorcontrib>Pachynski, Russell K.</creatorcontrib><title>Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial</title><title>European journal of cancer (1990)</title><addtitle>Eur J Cancer</addtitle><description>Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate cancer (mCRPC).
In the non-randomised, multicohort, global phase II CheckMate 9KD trial, 84 patients with chemotherapy-naive mCRPC, ongoing androgen deprivation therapy and ≤2 prior novel hormonal therapies (NHTs) received nivolumab 360 mg and docetaxel 75 mg/m2 every 3 weeks with prednisone 5 mg twice daily (≤10 cycles) and then nivolumab 480 mg every 4 weeks (≤2 years). The co-primary end-points were objective response rate (ORR) and prostate-specific antigen response rate (PSA50-RR; ≥50% decrease from baseline).
The confirmed ORR (95% confidence interval [CI]) was 40.0% (25.7–55.7), and the confirmed PSA50-RR (95% CI) was 46.9% (35.7–58.3). The median (95% CI) radiographic progression-free survival (rPFS) and overall survival (OS) were 9.0 (8.0–11.6) and 18.2 (14.6–20.7) months, respectively. In subpopulations with versus without prior NHT, the ORR was 38.7% versus 42.9%, the PSA50-RR was 39.6% versus 60.7%, the median rPFS was 8.5 versus 12.0 months and the median OS was 16.2 months versus not reached. Homologous recombination deficiency status or tumour mutational burden did not appear to impact efficacy. The most common any-grade and grade 3–4 treatment-related adverse events were fatigue (39.3%) and neutropenia (16.7%), respectively. Three treatment-related deaths occurred (1 pneumonitis related to nivolumab; 2 pneumonias related to docetaxel).
Nivolumab plus docetaxel has clinical activity in patients with chemotherapy-naïve mCRPC. Safety was consistent with the individual components. These results support further investigation in the ongoing phase III CheckMate 7DX trial.
NCT03338790.
•Nivolumab plus docetaxel has clinical activity in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.•Safety of the combination is consistent with that of the individual components.•These data support further investigation in the ongoing phase III CheckMate 7DX trial.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Castration</subject><subject>Chemotherapy</subject><subject>Clinical trial</subject><subject>Cohort Studies</subject><subject>Confidence intervals</subject><subject>Deprivation</subject><subject>Docetaxel</subject><subject>Docetaxel - pharmacology</subject><subject>Docetaxel - therapeutic use</subject><subject>Homologous recombination</subject><subject>Homology</subject><subject>Humans</subject><subject>Immunostimulation</subject><subject>Immunotherapy</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Metastatic castration-resistant prostate cancer</subject><subject>Microenvironments</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Neutropenia</subject><subject>Nivolumab</subject><subject>Nivolumab - pharmacology</subject><subject>Nivolumab - therapeutic use</subject><subject>Patients</subject><subject>Pneumonitis</subject><subject>Prednisone</subject><subject>Prostate cancer</subject><subject>Prostate-specific antigen</subject><subject>Prostatic Neoplasms, Castration-Resistant - drug therapy</subject><subject>Response rates</subject><subject>Subpopulations</subject><subject>Survival</subject><subject>Targeted cancer therapy</subject><subject>Tumor microenvironment</subject><subject>Tumors</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU2O1DAQhS0EYpqBC7BAltiwSbDjxLERG9T8tRhgA2vLcSqKm_xhOw1zF-7AIbgYFfXAggWrKvl99VTlR8hDznLOuHx6zOHobF6wgudM56wUt8iOq1pnTFXFbbJjutKZYqW-IPdiPDLGalWyu-RClIoVSpY78uODP83DOtqGLsMaaTs7SPY7DNRPdLHJw5Qi_eZTT10P45x6CHa5zib76-cJ6IhwTIg56rAJ2M1TFiB6fJ0SXcK8yYDq5CA8oyitAzp2YR4pmtGltxHo4UD3Pbgv7zdWv3tJU_B2uE_udHaI8OCmXpLPr1992r_Nrj6-OexfXGVOlEJkXS2g4K6RlatqLluJRXNoq7qRtq0lMkx1jRMNqzho1dqm7pRUZQlN24hKXJInZ19c9-sKMZnRRwfDYCeY12gKyZgqRMUEoo__QY_zGibcDqmiEoKXUiNVnCmH98cAnVmCH224NpyZLTtzNFt2ZsvOMG0wOxx6dGO9NiO0f0f-hIXA8zMA-BcnD8FEh_k4aH0Al0w7-__5_wbMV62p</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Fizazi, Karim</creator><creator>González Mella, Pablo</creator><creator>Castellano, Daniel</creator><creator>Minatta, Jose N.</creator><creator>Rezazadeh Kalebasty, Arash</creator><creator>Shaffer, David</creator><creator>Vázquez Limón, Juan C.</creator><creator>Sánchez López, Héctor M.</creator><creator>Armstrong, Andrew J.</creator><creator>Horvath, Lisa</creator><creator>Bastos, Diogo A.</creator><creator>Amin, Neha P.</creator><creator>Li, Jia</creator><creator>Unsal-Kacmaz, Keziban</creator><creator>Retz, Margitta</creator><creator>Saad, Fred</creator><creator>Petrylak, Daniel P.</creator><creator>Pachynski, Russell K.</creator><general>Elsevier Ltd</general><general>Elsevier Science Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3531-1920</orcidid><orcidid>https://orcid.org/0000-0001-7012-1754</orcidid><orcidid>https://orcid.org/0000-0002-3701-5084</orcidid><orcidid>https://orcid.org/0000-0002-8966-7631</orcidid></search><sort><creationdate>202201</creationdate><title>Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial</title><author>Fizazi, Karim ; González Mella, Pablo ; Castellano, Daniel ; Minatta, Jose N. ; Rezazadeh Kalebasty, Arash ; Shaffer, David ; Vázquez Limón, Juan C. ; Sánchez López, Héctor M. ; Armstrong, Andrew J. ; Horvath, Lisa ; Bastos, Diogo A. ; Amin, Neha P. ; Li, Jia ; Unsal-Kacmaz, Keziban ; Retz, Margitta ; Saad, Fred ; Petrylak, Daniel P. ; Pachynski, Russell K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3433-f73e21cb65c5716d6c5791ed57b6ad7643308fbc3b051e98dab7f86844ebdb353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Castration</topic><topic>Chemotherapy</topic><topic>Clinical trial</topic><topic>Cohort Studies</topic><topic>Confidence intervals</topic><topic>Deprivation</topic><topic>Docetaxel</topic><topic>Docetaxel - pharmacology</topic><topic>Docetaxel - therapeutic use</topic><topic>Homologous recombination</topic><topic>Homology</topic><topic>Humans</topic><topic>Immunostimulation</topic><topic>Immunotherapy</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Metastatic castration-resistant prostate cancer</topic><topic>Microenvironments</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Neutropenia</topic><topic>Nivolumab</topic><topic>Nivolumab - pharmacology</topic><topic>Nivolumab - therapeutic use</topic><topic>Patients</topic><topic>Pneumonitis</topic><topic>Prednisone</topic><topic>Prostate cancer</topic><topic>Prostate-specific antigen</topic><topic>Prostatic Neoplasms, Castration-Resistant - drug therapy</topic><topic>Response rates</topic><topic>Subpopulations</topic><topic>Survival</topic><topic>Targeted cancer therapy</topic><topic>Tumor microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fizazi, Karim</creatorcontrib><creatorcontrib>González Mella, Pablo</creatorcontrib><creatorcontrib>Castellano, Daniel</creatorcontrib><creatorcontrib>Minatta, Jose N.</creatorcontrib><creatorcontrib>Rezazadeh Kalebasty, Arash</creatorcontrib><creatorcontrib>Shaffer, David</creatorcontrib><creatorcontrib>Vázquez Limón, Juan C.</creatorcontrib><creatorcontrib>Sánchez López, Héctor M.</creatorcontrib><creatorcontrib>Armstrong, Andrew J.</creatorcontrib><creatorcontrib>Horvath, Lisa</creatorcontrib><creatorcontrib>Bastos, Diogo A.</creatorcontrib><creatorcontrib>Amin, Neha P.</creatorcontrib><creatorcontrib>Li, Jia</creatorcontrib><creatorcontrib>Unsal-Kacmaz, Keziban</creatorcontrib><creatorcontrib>Retz, Margitta</creatorcontrib><creatorcontrib>Saad, Fred</creatorcontrib><creatorcontrib>Petrylak, Daniel P.</creatorcontrib><creatorcontrib>Pachynski, Russell K.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fizazi, Karim</au><au>González Mella, Pablo</au><au>Castellano, Daniel</au><au>Minatta, Jose N.</au><au>Rezazadeh Kalebasty, Arash</au><au>Shaffer, David</au><au>Vázquez Limón, Juan C.</au><au>Sánchez López, Héctor M.</au><au>Armstrong, Andrew J.</au><au>Horvath, Lisa</au><au>Bastos, Diogo A.</au><au>Amin, Neha P.</au><au>Li, Jia</au><au>Unsal-Kacmaz, Keziban</au><au>Retz, Margitta</au><au>Saad, Fred</au><au>Petrylak, Daniel P.</au><au>Pachynski, Russell K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial</atitle><jtitle>European journal of cancer (1990)</jtitle><addtitle>Eur J Cancer</addtitle><date>2022-01</date><risdate>2022</risdate><volume>160</volume><spage>61</spage><epage>71</epage><pages>61-71</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate cancer (mCRPC).
In the non-randomised, multicohort, global phase II CheckMate 9KD trial, 84 patients with chemotherapy-naive mCRPC, ongoing androgen deprivation therapy and ≤2 prior novel hormonal therapies (NHTs) received nivolumab 360 mg and docetaxel 75 mg/m2 every 3 weeks with prednisone 5 mg twice daily (≤10 cycles) and then nivolumab 480 mg every 4 weeks (≤2 years). The co-primary end-points were objective response rate (ORR) and prostate-specific antigen response rate (PSA50-RR; ≥50% decrease from baseline).
The confirmed ORR (95% confidence interval [CI]) was 40.0% (25.7–55.7), and the confirmed PSA50-RR (95% CI) was 46.9% (35.7–58.3). The median (95% CI) radiographic progression-free survival (rPFS) and overall survival (OS) were 9.0 (8.0–11.6) and 18.2 (14.6–20.7) months, respectively. In subpopulations with versus without prior NHT, the ORR was 38.7% versus 42.9%, the PSA50-RR was 39.6% versus 60.7%, the median rPFS was 8.5 versus 12.0 months and the median OS was 16.2 months versus not reached. Homologous recombination deficiency status or tumour mutational burden did not appear to impact efficacy. The most common any-grade and grade 3–4 treatment-related adverse events were fatigue (39.3%) and neutropenia (16.7%), respectively. Three treatment-related deaths occurred (1 pneumonitis related to nivolumab; 2 pneumonias related to docetaxel).
Nivolumab plus docetaxel has clinical activity in patients with chemotherapy-naïve mCRPC. Safety was consistent with the individual components. These results support further investigation in the ongoing phase III CheckMate 7DX trial.
NCT03338790.
•Nivolumab plus docetaxel has clinical activity in men with chemotherapy-naïve metastatic castration-resistant prostate cancer.•Safety of the combination is consistent with that of the individual components.•These data support further investigation in the ongoing phase III CheckMate 7DX trial.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>34802864</pmid><doi>10.1016/j.ejca.2021.09.043</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-3531-1920</orcidid><orcidid>https://orcid.org/0000-0001-7012-1754</orcidid><orcidid>https://orcid.org/0000-0002-3701-5084</orcidid><orcidid>https://orcid.org/0000-0002-8966-7631</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2022-01, Vol.160, p.61-71 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2600823503 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Aged Aged, 80 and over Antigens Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Castration Chemotherapy Clinical trial Cohort Studies Confidence intervals Deprivation Docetaxel Docetaxel - pharmacology Docetaxel - therapeutic use Homologous recombination Homology Humans Immunostimulation Immunotherapy Male Metastases Metastasis Metastatic castration-resistant prostate cancer Microenvironments Middle Aged Monoclonal antibodies Neutropenia Nivolumab Nivolumab - pharmacology Nivolumab - therapeutic use Patients Pneumonitis Prednisone Prostate cancer Prostate-specific antigen Prostatic Neoplasms, Castration-Resistant - drug therapy Response rates Subpopulations Survival Targeted cancer therapy Tumor microenvironment Tumors |
| title | Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T08%3A59%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nivolumab%20plus%20docetaxel%20in%20patients%20with%20chemotherapy-na%C3%AFve%20metastatic%20castration-resistant%20prostate%20cancer:%20results%20from%20the%20phase%20II%20CheckMate%209KD%20trial&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Fizazi,%20Karim&rft.date=2022-01&rft.volume=160&rft.spage=61&rft.epage=71&rft.pages=61-71&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/j.ejca.2021.09.043&rft_dat=%3Cproquest_cross%3E2625331469%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2625331469&rft_id=info:pmid/34802864&rft_els_id=S0959804921011448&rfr_iscdi=true |